BioRestorative Therapies, Inc. (BRTX)
BRTX Stock Price Chart
Explore BioRestorative Therapies, Inc. interactive price chart. Choose custom timeframes to analyze BRTX price movements and trends.
BRTX Company Profile
Discover essential business fundamentals and corporate details for BioRestorative Therapies, Inc. (BRTX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
5 Dec 2012
Employees
11.00
Website
https://www.biorestorative.comCEO
Lance Alstodt
Description
BioRestorative Therapies, Inc. is a life sciences company dedicated to developing regenerative medicine products and therapies. Their approach primarily utilizes adult stem cell protocols to address two key areas: disc/spine disease and metabolic disorders. Within their disc/spine program, known as brtxDisc, the company's leading cell therapy candidate is BRTX-100. This treatment involves culturing mesenchymal stem cells harvested from a patient's own bone marrow (autologous) to provide a non-surgical solution for painful lumbosacral disc conditions. BRTX-100 has successfully completed Phase 1 clinical trials. The company is also advancing its Metabolic Program, named ThermoStem, which is currently in the preclinical stage. This cell-based therapy targets obesity and other metabolic ailments by employing brown adipose-derived stem cells to generate brown adipose tissue. Beyond these core programs, BioRestorative Therapies also offers an investigational curved needle device designed for delivering cells and various therapeutic materials to the spine and discs. The company fosters strategic research and development partnerships, including agreements with Rohto Pharmaceutical Co., Ltd., Pfizer, Inc., and the University of Pennsylvania. Founded in 1997 and headquartered in Melville, New York, the company was initially known as Stem Cell Assurance, Inc., before rebranding to BioRestorative Therapies, Inc. in August 2011.
BRTX Financial Timeline
Browse a chronological timeline of BioRestorative Therapies, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 Aug 2026
EPS estimate is -$0.15, while revenue estimate is $600.00k.
Earnings released on 14 May 2026
EPS came in at -$0.19 surpassing the estimated -$0.30 by +36.67%, while revenue for the quarter reached $575.00k , beating expectations by +84.00%.
Earnings released on 26 Mar 2026
EPS came in at -$0.37 matching the estimated -$0.37, while revenue for the quarter reached $20.00k , missing expectations by -86.67%.
Earnings released on 12 Nov 2025
EPS came in at -$0.33 surpassing the estimated -$0.36 by +8.33%, while revenue for the quarter reached $11.80k , missing expectations by -97.43%.
Earnings released on 12 Aug 2025
EPS came in at -$0.30 surpassing the estimated -$0.41 by +26.83%, while revenue for the quarter reached $303.30k , beating expectations by +51.65%.
Earnings released on 14 May 2025
EPS came in at -$0.56 falling short of the estimated -$0.32 by -75.00%, while revenue for the quarter reached $25.00k , missing expectations by -93.42%.
Earnings released on 27 Mar 2025
EPS came in at -$0.20 surpassing the estimated -$0.27 by +25.93%, while revenue for the quarter reached $43.30k , missing expectations by -90.88%.
Earnings released on 12 Nov 2024
EPS came in at -$0.13 surpassing the estimated -$0.43 by +69.77%, while revenue for the quarter reached $233.60k , missing expectations by -50.82%.
Earnings released on 13 Aug 2024
EPS came in at -$0.50 surpassing the estimated -$0.56 by +10.71%, while revenue for the quarter reached $89.10k , beating expectations by +791.00%.
Earnings released on 11 Jun 2024
EPS came in at -$0.33 surpassing the estimated -$0.51 by +35.29%, while revenue for the quarter reached $35.00k , beating expectations by +133.33%.
Earnings released on 29 Mar 2024
EPS came in at -$0.57 surpassing the estimated -$0.65 by +12.31%, while revenue for the quarter reached $19.30k , beating expectations by +93.00%.
Earnings released on 13 Nov 2023
EPS came in at -$0.64 surpassing the estimated -$0.68 by +5.88%, while revenue for the quarter reached $30.70k , beating expectations by +2.33%.
Earnings released on 11 Aug 2023
EPS came in at -$0.77 surpassing the estimated -$1.19 by +35.29%, while revenue for the quarter reached $64.50k , beating expectations by +545.00%.
Earnings released on 12 May 2023
EPS came in at -$1.53 falling short of the estimated -$1.26 by -21.43%, while revenue for the quarter reached $31.30k , beating expectations by +0.97%.
Earnings released on 24 Mar 2023
EPS came in at -$1.19 surpassing the estimated -$1.43 by +16.78%, while revenue for the quarter reached $3.70k .
Earnings released on 14 Nov 2022
EPS came in at -$1.28 surpassing the estimated -$1.45 by +11.72%, while revenue for the quarter reached $29.00k .
Earnings released on 15 Aug 2022
EPS came in at -$1.28 falling short of the estimated -$0.55 by -132.73%, while revenue for the quarter reached $71.10k .
Earnings released on 16 May 2022
EPS came in at $1.37 surpassing the estimated -$0.63 by +317.46%, while revenue for the quarter reached $16.00k , missing expectations by -73.38%.
Earnings released on 30 Mar 2022
EPS came in at -$6.90 falling short of the estimated -$0.54 by -1.18k%, while revenue for the quarter reached $5.00k .
Earnings released on 15 Nov 2021
EPS came in at -$4.99 , while revenue for the quarter reached $8.00k .
Stock split effective on 27 Oct 2021
Shares were split 1 : 4000 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 16 Aug 2021
EPS came in at -$4.85 , while revenue for the quarter reached $15.00k .
BRTX Stock Performance
Access detailed BRTX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
